HAYWARD, CA – Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that the US Patent and Trademark Office has issued US Patent No. 9,138,205 for a Sample Recovery and Collection Device.
The issuance of this patent is a first step towards our vision of providing efficient and simple to use biosample collection technologies. The recognition of our sample collection technology by leading researchers affirms that we are on the right track for fulfilling the mission our company has been founded upon, which is improving human and animal health assessment and research by enabling efficient, cost effective collection, preservation and transportation of biological samples,” said Dr. Bassam El-Fahmawi, President and CTO of Mawi DNA Technologies.
The patent covers the elements used in Mawi’s iSWAB technology , an integrated system that combines a unique biosample collection and concentration device with a variety of proprietary buffer formulations that enable room temperature stabilization of DNA, RNA, proteins, and oral samples for drug screening. Mawi DNA Technologies’ product development pipeline includes iSWAB-Blood designed to overcome current challenges in Dry Blood Spot collection, as well as a potentially disruptive new formula for stabilizing live, intact cells at ambient conditions for extended time periods.
About Mawi DNA Technologies:
Mawi DNA Technologies was founded in 2013 and has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. The company’s flagship product iSWAB-DNA has gained significant market traction due to its ability to be utilized for animals and all human population segments from infants to elderly, robust DNA yield, and low bacterial DNA content. Mawi DNA Technologies has established relationships with well known children’s hospitals for neonatal screening, and has set up an extensive network of international distributors to market and sell iSWAB products globally. For more information, please visit our website at https://mawidna.com
Candida Data Using iSWAB In Response to New Infectious Diseases...
A deadly fungal infection, Candida Auris, is becoming a serious threat. This drug-resistant strain is deadly for those with weakened immune systems and is spreading at an alarming rate. The READ MORE
Top Reasons to Ditch Your Current VTM. Upgrade your Viral…...
Mawi DNA has developed iSWAB-RC-EL, an FDA approved sample collection device for transport and storage of samples suspected of containing an infectious disease*. Why iSWAB-RC-EL is the superior op...READ MORE
Mawi DNA Announces Dr. Bouzyk as New Board Member!...
It is with great delight and excitement that we announce that Dr. READ MORE